AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05664906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese Medicine Oral Rinse Formula-I (CMORF-I)
Description: * Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~* Instruction to rinse:~  1. The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~ 2. Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~ 3. Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~ 4. Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~ 5. To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~ 6. 4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT.
Study NCT05664906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: • Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
Study NCT05664906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: • Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
Study NCT05664906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules, instruction is the same as CMORF-I.
Study NCT05185804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin
Description: 60 mg orally, 1 time per day
Study NCT05185804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clexane
Description: 40 mg subcutaneously, 1 time per day
Study NCT05722691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Stranded RNA sodium salt
Description: Once intramuscular injection 5 mg (1 vial)
Study NCT05722691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once intramuscular injection (1 vial)
Study NCT06270641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ExerciseRx intervention
Description: ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
Study NCT06249230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hematologic features
Description: Hematologic features include coagulation indicators, autoimmune indicators, and endocrine indicators.
Study NCT06249230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound indices of uterine artery blood flow
Description: Ultrasound indices of uterine artery blood flow include endometrial thickness, endometrial artery blood flow parameters , and bilateral uterine artery blood flow parameters.
Study NCT06249230 — intervention group
Intervention type: OTHER
Intervention: Demographic characteristics
Description: Demographic characteristics include age, the number of previous spontaneous abortions (including biochemical pregnancies), BMI, fertility history, past disease history, chromosomal status, family and genetic history, etc.
Study NCT04699773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LITT
Description: This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
Study NCT04699773 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
Study NCT06610084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise)
Description: Applications for experimental group 2 (progressive muscle relaxation exercise) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, progressive muscle relaxation exercise was performed face-to-face.~Session 2 (Week 33-34): Progressive muscle relaxation exercise was repeated with online interview.~Session 3 Week 35: In Phase 3, the progressive muscle relaxation exercise was repeated face-to-face.~Session 4 Week 36: Progressive muscle relaxation exercise was repeated online. Session 5 Week 37: Progressive muscle relaxation exercise, repeated face-to-face.~Session 6 38.-40th Week: It was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The video prepared by the researcher was used for the progressive relaxation exercise training given to the mother. The researcher guided the mothers to perform the practice once a day and follow-up was ensured through daily telephone calls.
Study NCT06610084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypno-breastfeeding
Description: Practices for experimental group 1 (Hypno-breastfeeding) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, hypno-breastfeeding practice was performed face-to-face.~Session 2 (33rd-34th week): Hypno-breastfeeding practice was repeated with online interviews.~Session 3 (35th week): Hypno-breastfeeding practice was repeated face-to-face. Session 4 (36th week): Hypno-breastfeeding practice was repeated online. Session 5 (37th week): Hypno-breastfeeding practice was repeated face-to-face. Session 6 (38th-40th week): Hypno-breastfeeding practice was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The audio recording prepared by the researcher was used for the hypno-breastfeeding application given to the mother. The researcher guided the mother to perform the application once a day and followed up with daily telephone calls.
Study NCT05878236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CyTOF Analysis
Description: CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
Study NCT06715618 — intervention group
Intervention type: OTHER
Intervention: FMS test
Description: Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
Study NCT06728969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MT1 Auditory startle response patterns analysis algorithm
Description: Objective measurements of attention and inhibition.
Study NCT06728969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T.O.V.A. Continuous Performance Test
Description: Objective measurements of attention and inhibitory control.
Study NCT06727864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-month regimen (2HERZ/2HRE)
Description: 4-month (2HERZ/2HRE)
Study NCT06727864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-month (2HERZ/4HRE)
Description: 2 months of HREZ followed by 4 months of HR/HRE
Study NCT06729619 — intervention group
Intervention type: DRUG
Intervention: The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.
Description: Blood and cerebrospinal fluid concentrations of anti-infective drugs such as vancomycin, meropenem, linezolid, cefoperazone sulbactam and ceftazidime ababactam will be monitored after the drug reaches a steady state.
Study NCT01005667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthTrack
Description: Measurement of cervical dilation and head station
Study NCT06288568 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04968236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Description: In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
Study NCT04968236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial Dry Needling
Description: This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
Study NCT04968236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive stretching
Description: Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
Study NCT04976816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator betamethasone injection
Description: The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate \&2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
Study NCT04976816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator triamcinolone injection
Description: The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
Study NCT04976816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator and retrobulbar betamethasone injection
Description: In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
Study NCT04976816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator and retrobulbar triamcinolone injection
Description: In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
Study NCT05393596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Software Intervention
Description: Virtual Reality Software Intervention
Study NCT05393596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software Intervention
Description: Virtual Reality Software Intervention
Study NCT05283746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Epetraborole hydrochloride 250 mg tablets for oral administration
Study NCT06550479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF
Description: Distal forearm AVF for hemodialysis.
Study NCT01408069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIGRANE
Description: 1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
Study NCT01408069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARCEL
Description: 1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
Study NCT05898516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study NCT06369480 — intervention group
Intervention type: PROCEDURE
Intervention: Resection/Ablation of tumor
Description: Curative treatment
Study NCT06369480 — intervention group
Intervention type: PROCEDURE
Intervention: Palliative chemotherapy
Description: Chemotherapeutic medications
Study NCT06369480 — intervention group
Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy
Description: Chemotherapeutic medications after surgery
Study NCT06369480 — intervention group
Intervention type: PROCEDURE
Intervention: Stereotatic radiotherapy
Description: Radiotherapy
Study NCT06369480 — intervention group
Intervention type: PROCEDURE
Intervention: Best supportive care
Description: Symptomatic treatment, non-curative treatment
Study NCT06330415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SME tool
Description: The intervention comprises of an open-access website targeting the employer of the sick-listed employee. The website provides practical resources, including templates, communication videos and information on legislation, workplace accommodations and most common reasons of sickness absence.
Study NCT05233735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel
Description: Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
Study NCT05233735 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Topical treatment
Description: betamethasone ointment treatment once per day
Study NCT05322096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-706
Description: Capsules~Oral administration
Study NCT05322096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules~Oral administration
Study NCT06000644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined group
Description: The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing for 30 minutes per session, 3 times a week for 4 weeks.
Study NCT06000644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive group
Description: The cognitive group will receive cognitive training while treadmill walking with a progressive speed for 30 minutes per session, 3 times a week for 4 weeks .
Study NCT06000644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic group
Description: The rhythmic group will hear rhythmic auditory stimulation while treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
Study NCT06000644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill group
Description: The treadmill group will train only in progressive treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
Study NCT04623710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Study NCT06140186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Timolol
Description: Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
Study NCT06140186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate
Description: Betamethasone valerate 0.1% cream application twice daily
Study NCT04809116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
Study NCT05339958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol® Men Hair Growth Nutraceutical
Description: Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
Study NCT05339958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: The placebo capsules contain no active ingredients.
Study NCT05143424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine sulfate 30 mg tablets as a single dose twice
Study NCT06326736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.
Study NCT06326736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered 6 weeks post-tumor resection.
Study NCT06326736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SJ-Neo006
Description: SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).
Study NCT06326736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+Abraxane
Description: Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
Study NCT06261723 — intervention group
Intervention type: PROCEDURE
Intervention: non-chirurgical periodontal treatment
Description: The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.
Study NCT05691543 — intervention group
Intervention type: PROCEDURE
Intervention: sacrospinous fixation Using Posterior Vaginal wall flap
Description: * Identification of the sacro spinous ligament.~* Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~* Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,
Study NCT04862338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide (NMN-C)
Description: Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
Study NCT04582656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted microwave ablation
Description: Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
Study NCT06454786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation Method
Description: Management of cardiogenic shock scenario on an advanced simulation mannequin
Study NCT04873726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplication
Description: Magnetic tape® is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
Study NCT04873726 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape
Description: Kinesiology tape is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
Study NCT05731310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Pill
Description: Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
Study NCT05589974 — intervention group
Intervention type: DRUG
Intervention: Verteporfin
Description: Chronic CSC are receiving one treatment before the observation period.
Study NCT05148728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic fulguration
Description: already included. WE will use Storz monopolar device for fulguration
Study NCT05605353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal microbiota sampling and blood sampling
Description: There is no intervention in this study. We will obtain faeces and blood from the recruited patients and assess the microbiota and their metabolites therein. This is an observational work
Study NCT05462574 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT06472739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF mouthwash four times per day at radiotherapy initiate, during the whole radiotherapy phase
Study NCT04688632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampreloxetine <Dose A>
Description: Ampreloxetine \<Dose A> will be administered as 1 tablet of \<Dose A> and 3 tablets of Ampreloxetine Placebo.